Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

BACKGROUND: NanoString’s Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based on the PAM50 gene expression signature. The test outputs a risk of recurrence (ROR) score, risk category, and intrinsic subtype (Luminal A/B, HER2-enriched, Basal-like). The studies described here were designed...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Torsten, Wallden, Brett, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Gao, Dongxia, Barry, Garrett, Dowidar, Naeem, Maysuria, Malini, Storhoff, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008304/
https://www.ncbi.nlm.nih.gov/pubmed/24625003
http://dx.doi.org/10.1186/1471-2407-14-177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008304/
https://www.ncbi.nlm.nih.gov/pubmed/24625003
http://dx.doi.org/10.1186/1471-2407-14-177

Ejemplares similares